217 related articles for article (PubMed ID: 9614446)
21. Pathology is a necessary and informative tool in oncology clinical trials.
Nagtegaal ID; West NP; van Krieken JH; Quirke P
J Pathol; 2014 Jan; 232(2):185-9. PubMed ID: 24037805
[TBL] [Abstract][Full Text] [Related]
22. The organization of clinical trials for oncology at IRCCS Istituto Nazionale Tumori "Fondazione G. Pascale" Napoli and the impact of the OECI accreditation process.
De Feo G; D'Ambrosio F; Palmieri G; Perrone F; Ciliberto G
Tumori; 2015; 101 Suppl 1():S33-7. PubMed ID: 27096270
[TBL] [Abstract][Full Text] [Related]
23. [Post launch studies].
Akaza H; Ohashi Y; Shimada Y; Ikeda T; Saijo N; Isonishi S; Hirao Y; Tsuruo T; Tsukagoshi S; Sone S; Nakamura S; Kato M; Mikami O; von Euler M; Blackledge G; Milsted B; Vose B
Gan To Kagaku Ryoho; 2002 Nov; 29(11):2037-48. PubMed ID: 12465411
[TBL] [Abstract][Full Text] [Related]
24. Survival of Patients With Advanced or Metastatic Renal Cell Carcinoma in Routine Practice Differs From That in Clinical Trials-Analyses From the German Clinical RCC Registry.
Marschner N; Staehler M; Müller L; Nusch A; Harde J; Koska M; Jänicke M; Goebell PJ;
Clin Genitourin Cancer; 2017 Apr; 15(2):e209-e215. PubMed ID: 27720164
[TBL] [Abstract][Full Text] [Related]
25. Barriers to enrollment in non-small cell lung cancer therapeutic clinical trials.
Baggstrom MQ; Waqar SN; Sezhiyan AK; Gilstrap E; Gao F; Morgensztern D; Govindan R
J Thorac Oncol; 2011 Jan; 6(1):98-102. PubMed ID: 21150469
[TBL] [Abstract][Full Text] [Related]
26. Society of Gynecologic Oncology meeting highlights progress.
Jenks S
J Natl Cancer Inst; 2011 Apr; 103(7):533-4. PubMed ID: 21436060
[No Abstract] [Full Text] [Related]
27. Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy--a representative sample survey in Germany.
Link H; Nietsch J; Kerkmann M; Ortner P;
Support Care Cancer; 2016 Jan; 24(1):367-376. PubMed ID: 26081593
[TBL] [Abstract][Full Text] [Related]
28. [Consistency in the analysis and reporting of PEPs in oncology randomized controlled trials from registration to publication: a systematic review].
Boespflug A; Gan H; Chen EX; Pond G; You B
Bull Cancer; 2012 Oct; 99(10):943-52. PubMed ID: 23034429
[TBL] [Abstract][Full Text] [Related]
29. [Japan Clinical Oncology Group for cooperative cancer clinical trials and role of the statistical center in the management of cancer clinical trials].
Shimoyama M; Tajima K
Gan To Kagaku Ryoho; 1993 Dec; 20(16):2507-18. PubMed ID: 8279849
[TBL] [Abstract][Full Text] [Related]
30. The history and future of the Urologic Oncology Study Group (UOSG) of the Japan Clinical Oncology Group (JCOG).
Tobisu K
Jpn J Clin Oncol; 2012 May; 42(5):363-7. PubMed ID: 22450928
[TBL] [Abstract][Full Text] [Related]
31. Cancer clinical trials in the USA: patient eligibility, generalizability of results and technology transfer.
Begg CB
Bull Cancer; 1987; 74(2):197-203. PubMed ID: 3607303
[TBL] [Abstract][Full Text] [Related]
32. Reflections on medical oncology: an appeal for better clinical trials and improved reporting of their results.
Tannock I; Murphy K
J Clin Oncol; 1983 Jan; 1(1):66-70. PubMed ID: 6668484
[No Abstract] [Full Text] [Related]
33. Are clinical trial eligibility criteria an accurate reflection of a real-world population of advanced non-small-cell lung cancer patients?
Al-Baimani K; Jonker H; Zhang T; Goss GD; Laurie SA; Nicholas G; Wheatley-Price P
Curr Oncol; 2018 Aug; 25(4):e291-e297. PubMed ID: 30111974
[TBL] [Abstract][Full Text] [Related]
34. [Current problems of early phase clinical trials for new anticancer agents in Japan].
Nakagawa K; Fukuoka M
Gan To Kagaku Ryoho; 2000 Jun; 27(6):925-9. PubMed ID: 10897223
[TBL] [Abstract][Full Text] [Related]
35. Cancer incidence in Japan, 1985-89: re-estimation based on data from eight population-based cancer registries. The Research Group for Population-based Cancer Registration in Japan.
Jpn J Clin Oncol; 1998 Jan; 28(1):54-67. PubMed ID: 9491144
[TBL] [Abstract][Full Text] [Related]
36. Eligibility of real-world patients with chemo-refractory, K-RAS wild-type, metastatic colorectal cancer for palliative intent regorafenib monotherapy.
Angeles A; Hung W; Cheung WY
Med Oncol; 2018 Jun; 35(8):114. PubMed ID: 29936654
[TBL] [Abstract][Full Text] [Related]
37. Cross-boundary cancer studies at the University of Tokyo: Oncology in Asian countries: clinical development challenges and opportunities.
Rigaudy P
Jpn J Clin Oncol; 2014 Feb; 44 Suppl 1():i54-59. PubMed ID: 24516214
[No Abstract] [Full Text] [Related]
38. [Complementary Medicine in Oncology - difficult to claim effectiveness, quality and efficiency].
Melchart D
Forsch Komplementmed; 2015; 22(1):8-9. PubMed ID: 25824398
[No Abstract] [Full Text] [Related]
39. Japan Clinical Oncology Group (JCOG).
Shimoyama M; Fukuda H; Saijo N; Yamaguchi N
Jpn J Clin Oncol; 1998 Mar; 28(3):158-62. PubMed ID: 9614436
[TBL] [Abstract][Full Text] [Related]
40. [Clinical and epidemiological cancer registries: two complementary sources of information on cancer incidence].
Hofstädter F; Hentschel S
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Jan; 57(1):27-32. PubMed ID: 24357169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
